Mustang Bio to process rare cancer drug in Worcester
PHOTO | Courtesy of Mustang Bio
Mustang Bio's building in Worcester.
The company announced Thursday an Orphan Drug Designation from the U.S. Food and Drug Administration for MB-102, which the company hopes can treat blastic plasmacytoid dendritic cell neoplasm (BPDCN), a deadly blood cancer with a medial survival less than 18 months.
Mustang will process MB-102 in its newly built CAR-T cell therapy manufacturing facility at UMass Medicine Science Park.
In a statement, Martina Sersch, chief medical officer at the company, said the drug has the potential to address an area of high unmet medical need.
"This significant milestone for Mustang will provide additional market exclusivity and financial benefits to advance MB-102, which we believe is an important new treatment for patients with BPDCN,” Sersch said.
The drug is being studied at a California research center, hospital and medical school in a first-in-human, phase 1 clinical trial to evaluate the safety and anti-tumor activity of the drug in patients with relapsed or refractory acute myeloid leukemia and BPDCN.
The company last month said early results from the study have been positive.
WBJ Web Partners
Most Recent
Most Recent
0 Comments